Kurtis Francis Budden

Dr. Kurtis Francis Budden

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 February 2024 in Gut
Verified
Journal Article
Closed access
PDF file
Kurtis Francis BuddenKurtis Francis Budden
Kurtis Francis Budden
SSShakti Shukla
Shakti Shukla
KBKate L Bowerman
Kate L Bowerman
AVAnnalicia Vaughan
Annalicia Vaughan
SGShaan L Gellatly
Shaan L Gellatly
PHPhilip M. Hansbro
Philip M. Hansbro
Objective: Chronic obstructive pulmonary disease (COPD) is a major cause of global illness and death, most commonly caused by cigarette smoke. The mechanisms of pathogenesis remain poorly understood, limiting the development of effective therapies. The gastrointestinal microbiome has been implicated in chronic lung diseases via the gut-lung axis, but its role is unclear. Design: Using an in vivo mouse model of cigarette smoke (CS)-induced COPD and faecal microbial transfer (FMT), we characterised the faecal microbiota using metagenomics, proteomics and metabolomics. Findings were correlated with airway and systemic inflammation, lung and gut histopathology and lung function. Complex carbohydrates were assessed in mice using a high resistant starch diet, and in 16 patients with COPD using a randomised, double-blind, placebo-controlled pilot study of inulin supplementation. Results: FMT alleviated hallmark features of COPD (inflammation, alveolar destruction, impaired lung function), gastrointestinal pathology and systemic immune changes. Protective effects were additive to smoking cessation, and transfer of CS-associated microbiota after antibiotic-induced microbiome depletion was sufficient to increase lung inflammation while suppressing colonic immunity in the absence of CS exposure. Disease features correlated with the relative abundance of Muribaculaceae, Desulfovibrionaceae and Lachnospiraceae family members. Proteomics and metabolomics identified downregulation of glucose and starch metabolism in CS-associated microbiota, and supplementation of mice or human patients with complex carbohydrates improved disease outcomes. Conclusion: The gut microbiome contributes to COPD pathogenesis and can be targeted therapeutically.

Verified
Journal Article
Open access
PDF file
Kurtis Francis BuddenKurtis Francis Budden
Kurtis Francis Budden
SGShaan L. Gellatly
Shaan L. Gellatly
AVAnnalicia Vaughan
Annalicia Vaughan
NANadia M Lopes Amorim
Nadia M Lopes Amorim
JHJay Horvat
Jay Horvat
PHPhilip M. Hansbro
Philip M. Hansbro
Bifidobacterium are prominent gut commensals that produce the short-chain fatty acid (SCFA) acetate, and they are often used as probiotics. Connections between the gut and the lung, termed the gut–lung axis, are regulated by the microbiome. The gut–lung axis is increasingly implicated in cigarette smoke-induced diseases, and cigarette smoke exposure has been associated with depletion of Bifidobacterium species. In this study, we assessed the impact of acetate-producing Bifidobacterium longum subsp. longum (WT) and a mutant strain with an impaired acetate production capacity (MUT) on cigarette smoke-induced inflammation. The mice were treated with WT or MUT B. longum subsp. longum and exposed to cigarette smoke for 8 weeks before assessments of lung inflammation, lung tissue gene expression and cecal SCFAs were performed. Both strains of B. longum subsp. longum reduced lung inflammation, inflammatory cytokine expression and adhesion factor expression and alleviated cigarette smoke-induced depletion in caecum butyrate. Thus, the probiotic administration of B. longum subsp. longum, irrespective of its acetate-producing capacity, alleviated cigarette smoke-induced inflammation and the depletion of cecal butyrate levels.

4 February 2026 in British Journal of Nutrition
Verified
Journal Article
Open access
PDF file
BBBronwyn Berthon
Bronwyn Berthon
EWEvan Williams
Evan Williams
LWLily May Williams
Lily May Williams
Kurtis Francis BuddenKurtis Francis Budden
Kurtis Francis Budden
SHSarah A. Hiles
Sarah A. Hiles
Lisa WoodLisa Wood
Lisa Wood
This randomised controlled trial examined the effect of a 4-week, high-dose (Lf-High, 600 mg/d) or low-dose (Lf-Low, 200 mg/d) oral lactoferrin (Lf) intervention v . placebo on immune cell responses to respiratory virus, immune cell subsets and systemic inflammation. In healthy older adults ( n 103, ≥50 years old), ex vivo cytokine release of interferon (IFN)-α2, IFN-γ, IL-6 and TNF-α from rhinovirus A-16 (RV-16) or influenza A virus (H1N1) stimulated peripheral blood mononuclear cells, circulating immune cell subsets, and plasma IL-6, C-reactive protein (CRP) and TNF-α were assessed. Ninety-seven participants completed the 4-week intervention (Lf-High n 32, Lf-Low n 31, placebo n 34, withdrawals n 6). There was no difference in RV-16 or H1N1-induced IFN-γ release between groups. RV-16-induced IL-6 was lower in Lf-High v . placebo ( P = 0·001), and RV-16-induced IFN-α2 was higher in Lf-High v . Lf-Low ( P = 0·04). Lf-High increased total T cells ( P = 0·03) and CD4 + T cells ( P = 0·03) v . placebo. Lf-Low reduced neutrophil ( P = 0·04), natural killer cell ( P = 0·045), activated CD8 + T cell ( P = 0·03) and γδ T cell ( P = 0·03) frequency v . placebo. Plasma IL-6 ( P = 0·004) and CRP ( P = 0·03) were lower following Lf-High v . Lf-Low, but not placebo. Both high- and low-dose Lf altered ex vivo immune cell responses after 4 weeks. High-dose increased T-cell subsets, promoting adaptive immunity, and reduced systemic inflammation, while low-dose reduced proinflammatory and cytotoxic immune cells. High- and low-dose Lf supplements may have immunoceutical benefits in older adults.

Verified
Journal Article
Open access
PDF file
NANikhil Awatade
Nikhil Awatade
Kurtis Francis BuddenKurtis Francis Budden
Kurtis Francis Budden
PPPrabuddha S Pathinayake
Prabuddha S Pathinayake
ARAndrew T. Reid
Andrew T. Reid
KNKristy S. Nichol
Kristy S. Nichol
PWPeter AB Wark
Peter AB Wark
Increasing evidence suggests that acquired dysfunction of the cystic fibrosis transmembrane conductance regulator (CFTR) anion channel occurs as a result of cigarette smoke exposure in chronic obstructive pulmonary disease (COPD). CFTR-targeted therapies were developed to treat genetic CFTR defects in cystic fibrosis, but they have not demonstrated consistent clinical efficacy in small trials of patients with COPD. Here, we aimed to characterize CFTR and other ion channel activity and ciliation in primary bronchial epithelial cells (pBECs) from COPD donors compared with healthy controls, and to determine the extent to which CFTR dysfunction can be rescued by clinically relevant CFTR modulators. Air–liquid interface (ALI) cultures generated from conditionally reprogrammed (CR) primary bronchial epithelial cells (pBECs) obtained from healthy controls (n = 7) and COPD donors (n = 7) were assessed for transepithelial electrical resistance, immunofluorescence, cilia activity, ion channel function and expression of cell-type-associated markers at the transcript level. COPD cultures exhibited reduced ciliated area, accompanied by significantly decreased forskolin/IBMX-stimulated CFTR-mediated anion transport and ATP-induced calcium-activated chloride currents compared with healthy-control cultures, despite comparable CFTR mRNA expression. Treatment with CFTR potentiators (VX-770, GLPG1837 and icenticaftor) resulted in modest and highly variable functional responses, with no statistically significant improvement compared with vehicle-treated controls. CFTR function was not significantly associated with cumulative smoking exposure (pack-years) in this cohort, suggesting that smoking burden alone may not account for the observed inter-individual variability in acquired CFTR dysfunction. Collectively, these findings demonstrate abnormalities in ion transport and ciliation in the COPD airway epithelium consistent with an acquired CFTR dysfunction phenotype, but indicate that these abnormalities are not readily reversed by the tested CFTR potentiators. These results highlight differences between genetic and acquired CFTR dysfunction and underscore the need for alternative or combinatorial therapeutic strategies targeting epithelial dysfunction in COPD.

19 October 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
Kurtis Francis BuddenKurtis Francis Budden
Kurtis Francis Budden
SSShakti D. Shukla
Shakti D. Shukla
KBKate L. Bowerman
Kate L. Bowerman
SGShaan Gellatly
Shaan Gellatly
DWDavid L.A. Wood
David L.A. Wood
PHPhilip M. Hansbro
Philip M. Hansbro
Objective: Chronic obstructive pulmonary disease (COPD) is a major cause of global illness and death, most commonly caused by cigarette smoke. The mechanisms of pathogenesis remain poorly understood, limiting the development of effective therapies. The gastrointestinal microbiome has been implicated in chronic lung diseases via the gut-lung axis, but its role is unclear. Design: Using an in vivo mouse model of cigarette smoke-induced COPD and fecal microbial transfer (FMT), we characterized the fecal microbiota using metagenomics, proteomics and metabolomics. Findings were correlated with airway and systemic inflammation, lung and gut histopathology, and lung function. Complex carbohydrates were assessed in mice using a high resistant starch diet, and in sixteen COPD patients using a randomized, double-blind, placebo-controlled pilot study of inulin supplementation. Results: FMT alleviated hallmark features of COPD (inflammation, alveolar destruction, impaired lung function), gastrointestinal pathology and systemic immune changes. Protective effects were additive to smoking cessation. Disease features correlated with the relative abundance of Muribaculaceae, Desulfovibrionaceae and Lachnospiraceae family members. Proteomics and metabolomics identified downregulation of glucose and starch metabolism in cigarette smoke-associated microbiota, and supplementation of mice or human patients with complex carbohydrates improved disease outcomes. Conclusion: The gut microbiome contributes to COPD pathogenesis and can be targeted therapeutically. What is already known on this topic: Changes in gut microbiota are associated with COPD but the underlying host and microbial mechanisms are unclear, limiting the therapeutic applications. What this study adds: Microbiome composition and metabolism is reproducibly correlated with lung and gastrointestinal pathology in experimental COPD. Microbiome modifying interventions effectively alleviate disease, including protective effects supplementing smoking cessation. Nutritional interventions targeting the microbiome in COPD patients demonstrate efficacy in a small pilot study. How this study might affect research, practice or policy: Microbiome-targeting therapeutics and nutritional interventions may be developed for COPD, including as supplements to smoking cessation.

12 April 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
NANikhil Awatade
Nikhil Awatade
ARAndrew T Reid
Andrew T Reid
KNKristy S Nichol
Kristy S Nichol
Kurtis Francis BuddenKurtis Francis Budden
Kurtis Francis Budden
PVPunnam Chander Veerati
Punnam Chander Veerati
PWPeter Wark
Peter Wark
Introduction: Primary air liquid interface (ALI) cultures of bronchial epithelial cells are used extensively to model airway responses. A recent advance is the development of conditional reprogramming that enhances proliferative capability. Several different media and protocols are utilized, yet even subtle differences may influence cellular responses. We compared the morphology and functional responses, including innate immune responses to rhinovirus infection in conditionally reprogrammed primary bronchial epithelial cells (pBECs) differentiated using two commonly used culture media. Methods: pBECs from healthy participants (n = 5) were CR using γ-irradiated 3T3 fibroblasts and Rho Kinase inhibitor. CRpBECs were differentiated at ALI in either PneumaCult™ (PN-ALI) or Bronchial Epithelial Growth Medium (BEGM)-based differentiation media (BEBM:DMEM, 50:50, Lonza™) - (AB-ALI) for 28 days. Transepithelial electrical resistance (TEER), immunofluorescence, histology, cilia activity, ion channel function, and expression of cell markers were analyzed. Viral load was assessed by RT-qPCR and anti-viral factors quantified by Legendplex following Rhinovirus-A1b (RVA1b) infection. Results: CRpBECs differentiated in PneumaCult™ were smaller and had a lower TEER and cilia beat frequency (CBF) compared to BEGM media. PneumaCult™ media cultures exhibited significantly increased FOXJ1 expression, more ciliated cells with a larger active area, increased intracellular mucins, and increased calcium-activated chloride channel current. However, there were no significant changes in viral RNA or host antiviral responses. Conclusion: There are distinct structural and functional differences in CRpBECs cultured in the two commonly used ALI differentiation media. Such factors need to be taken into consideration when designing and comparing CRpBECs ALI experiments.